The second part of the hearing focused on drug interactions, regulatory suggestions, and the quality of CBD products for sale.
We have a lot to learn about how CBD interacts with other drugs. Including how they help or hinder how prescriptions work.
Don’t buy Diamond CBD. These product have been in the news a few times. A prominent, successful website is not a reason to purchase products from a brand.
The level of THC in products is a concern. This matters because it can cause unintended intoxication, affect how prescription drugs work, and make people fail a drug test.
Labeling is one of the biggest issues facing the industry. It’s also one of the best opportunities for regulatory action. To hold a brand accountable to what is on the label and to standardize the way brands present cannabinoid content on labels could bring enormous clarity to the space.
Manufacturers would like to be compliant. One requested an auditing process that would allow them to abide certain standards and build processes around regulations.
$30,000-40,000/acre on CBD product versus $700/acre for fiber means nearly all hemp farmers are interested in making products for consumption.
Here’s a few highlights from speaker presentations:
In case there were any questions, never buy products that look like this.
A representative from the University of Mississippi put forward regulatory recommendations.
Clean Label Project summarizes findings on product quality and labeling.
A lawyer suing marijuana companies calls Colorado a "narco state" and warns agains pot.